Ferring International Center has patented a pharmaceutical composition containing bacteriophages targeting adherent-invasive E. coli strains for treating inflammatory bowel disease. The composition includes specific bacteriophage strains and a pharmaceutically acceptable carrier. This innovation offers a novel approach to combatting the disease. GlobalData’s report on Ferring International Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Ferring International Center SA - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ferring International Center, was a key innovation area identified from patents. Ferring International Center's grant share as of February 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11918613B2) discloses a pharmaceutical composition comprising bacteriophages capable of inducing a lytic infection in an adherent-invasive Escherichia coli strain. The composition includes specific bacteriophages of strains P2, P8, and CLB P2, deposited with the French National Collection of Microorganisms at the Institut Pasteur, along with a pharmaceutically acceptable carrier containing various auxiliary agents. The bacteriophages in the composition are lyophilized and can be administered through various routes such as oral, rectal, nasal, or topical, with specific dosage forms like pills, tablets, suppositories, or enemas.

Furthermore, the patent claims encompass different formulations and dosages of the composition, ranging from oral administration in various forms to rectal administration in suppositories or enemas. The dosage forms contain specific quantities of bacteriophages per dose, ensuring efficacy in targeting the adherent-invasive Escherichia coli strain. Additionally, the composition may include other bacteriophages from strains P1, P3, P4, P5, and P6, deposited with the French National Collection of Microorganisms at the Institut Pasteur, to enhance its lytic activity and sequence identity. This patent highlights the potential of bacteriophages as a targeted therapeutic approach against specific bacterial strains, offering a novel pharmaceutical composition for combating infections caused by adherent-invasive Escherichjson E. coli.

To know more about GlobalData’s detailed insights on Ferring International Center, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies